Home » Stocks » FBRX

Forte Biosciences, Inc. (FBRX)

Stock Price: $32.64 USD 0.64 (2.00%)
Updated May 7, 2021 4:00 PM EDT - Market closed
After-hours: $33.25 +0.61 (1.87%) May 7, 7:57 PM
Market Cap 444.60M
Revenue (ttm) n/a
Net Income (ttm) -46.49M
Shares Out 7.36M
EPS (ttm) -6.32
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 7
Last Price $32.64
Previous Close $32.00
Change ($) 0.64
Change (%) 2.00%
Day's Open 32.33
Day's Range 31.29 - 33.61
Day's Volume 189,719
52-Week Range 13.35 - 53.99

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

TORRANCE, Calif.--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company, will be providing first quarter 2021 results and a general bus...

4 days ago - Business Wire

TORRANCE, Calif.--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company announces fourth quarter and full year 2020 results and provide...

1 month ago - Business Wire

TORRANCE, Calif.--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company, will be providing 4Q and full year 2020 results and provide a ...

1 month ago - Business Wire

TORRANCE, Calif.--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company, announced today that Paul Wagner, Ph.D., CEO of Forte Bioscien...

2 months ago - Business Wire

TORRANCE, Calif.--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company, announced today announced that Paul Wagner, Ph.D., CEO of Fort...

2 months ago - Business Wire

TORRANCE, Calif.--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company, today announced the issuance of equity inducement awards as re...

2 months ago - Business Wire

FB-401 is a unique approach to atopic dermatitis containing three strains of bacteria that have shown the ability to induce tissue repair and reduce inflammation. FB-401 may present efficacy and safety ...

4 months ago - Seeking Alpha

TORRANCE, Calif.--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company, announced today announced that Paul Wagner, Ph.D., CEO of Fort...

5 months ago - Business Wire

TORRANCE, Calif.--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company, today announced the issuance of an equity inducement award as ...

5 months ago - Business Wire

TORRANCE, Calif.--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company, announced today announced that Paul Wagner, Ph.D., CEO of Fort...

5 months ago - Business Wire

TORRANCE, Calif.--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company, today announced third quarter 2020 financial results and provi...

5 months ago - Business Wire

TORRANCE, Calif.--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company, today announced that it will release third quarter 2020 result...

6 months ago - Business Wire

TORRANCE, Calif.--(BUSINESS WIRE)--Forte Biosciences, Inc. (NASDAQ: FBRX), a clinical-stage biopharmaceutical company, announced today the closing of its previously announced underwritten public offerin...

6 months ago - Business Wire

TORRANCE, Calif.--(BUSINESS WIRE)--FORTE BIOSCIENCES ANNOUNCES PRICING OF $40.0 MILLION PUBLIC OFFERING OF COMMON STOCK

6 months ago - Business Wire

TORRANCE, Calif.--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company, today announced that it has commenced an underwritten public o...

6 months ago - Business Wire

TORRANCE, Calif.--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FD...

6 months ago - Business Wire

TORRANCE, Calif.--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company, today announced that the first patient has been dosed in the c...

7 months ago - Business Wire

TORRANCE, Calif.--(BUSINESS WIRE)--Forte Biosciences, Inc.

7 months ago - Business Wire

Forte Biosciences (NASDAQ: FBRX) shares are trading higher on Friday after getting two upgrades.

8 months ago - Benzinga

About FBRX

Forte Biosciences Inc. operates as a clinical-stage biopharmaceutical company in the United States. It is developing a live biotherapeutic FB-401 that has completed Phase 1/2a clinical trial to treat inflammatory skin diseases for pediatric atopic dermatitis patients. The company was incorporated in 2007 and is based in Torrance, California.

Industry
Biotechnology
CEO
Martin Duvall
Employees
9
Stock Exchange
NASDAQ
Ticker Symbol
FBRX
Full Company Profile

Financial Performance

Financial Statements